Connecting and Collaborating on Cardiometabolic Care

Until recently, when a patient was diagnosed with HCM, symptom management was the only therapy available.

Now, with two approved treatments, Mavacamptin and Afacamptin, shared decision-making is more important than ever to ensure that patients, family members, and caregivers understand available treatment options.

I'm Yvonne Commodore-Menta, Board President for PCNA.

I'd like to welcome you to Heart to Heart Nurses.

PCNA supports your professional journey with accessible continuing education, practical patient resources, and a vibrant community that understands the unique challenges and rewards of cardiovascular nursing.

Together, we're advancing the knowledge that defines excellence in cardiac care while celebrating the difference you make every day.

Welcome to today's episode, the second in a two-part series on cardiometabolic care.

I'd like to welcome our guests, Joe Sassine and Emily Bankhead.